The Activation of PDGFRβ on Mononuclear Stromal/Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment. An Immunohistochemical Study of Five Cases
暂无分享,去创建一个
M. Szendrői | Z. Sápi | Z. Pápai | I. Antal | Zoltán Lippai | K. Dezső | Tamás Perlaky | T. Perlaky
[1] P. Hogendoorn,et al. Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis , 2021, Cancers.
[2] J. Neradil,et al. New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling , 2021, Cancers.
[3] L. Aponte-Tinao,et al. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation , 2021, Scientific Reports.
[4] J. Blay,et al. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab , 2021, BMC Cancer.
[5] Xi Chen,et al. Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis , 2020, BMC Musculoskeletal Disorders.
[6] H. Gelderblom,et al. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone , 2019, Current opinion in oncology.
[7] K. Ghaffarzadehgan,et al. Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review. , 2018, The archives of bone and joint surgery.
[8] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[9] A. Flanagan,et al. H3F3A (Histone 3.3) G34W Immunohistochemistry , 2017, The American journal of surgical pathology.
[10] G. Farfalli,et al. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls. , 2017, Human pathology.
[11] J. Blay,et al. Giant cell tumour of bone in the denosumab era. , 2017, European journal of cancer.
[12] A. Flanagan,et al. H 3 F 3 A ( Histone 3 . 3 ) G 34 W Immunohistochemistry A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone , 2017 .
[13] A. Flanagan,et al. Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone , 2017 .
[14] R. Mohankumar,et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. , 2016, European journal of cancer.
[15] G. Matcuk,et al. Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy , 2015, Skeletal Radiology.
[16] M. Stratton,et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.
[17] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[18] David M. Thomas,et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. , 2010, The Lancet. Oncology.
[19] P. Hogendoorn,et al. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array‐CGH analysis , 2009, Genes, chromosomes & cancer.
[20] M. Szendrői,et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. , 2008, The Journal of bone and joint surgery. American volume.
[21] M. Balke,et al. Giant cell tumor of bone: treatment and outcome of 214 cases , 2008, Journal of Cancer Research and Clinical Oncology.
[22] A. Evdokiou,et al. RANK Expression as a Cell Surface Marker of Human Osteoclast Precursors in Peripheral Blood, Bone Marrow, and Giant Cell Tumors of Bone , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[23] H. Yoshida,et al. Giant cell tumor of bone , 2004, Virchows Archiv A.
[24] M. Szendröi. Giant-cell tumour of bone. , 2004, The Journal of bone and joint surgery. British volume.
[25] E. Milgrom,et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. , 2002, American journal of clinical pathology.